Virtual Reality as a Motor Priming Tool for Cognitive-Motor Rehabilitation Among Sub-Acute Stroke Patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Stroke
- Sponsor
- Ziauddin University
- Enrollment
- 62
- Locations
- 1
- Primary Endpoint
- Sensorimotor function of hemiplegic upper extremity (Pre-Treatment)
- Last Updated
- 5 years ago
Overview
Brief Summary
Stroke is the second leading global cause of mortality counting for 6.5 million deaths per annum. The global prevalence of stroke is increasing with an estimated prevalence of 33 million per year, affecting 1 out of 6 individuals during their lifetime. The international data suggests the overall economic burden in Asia is projected to be increased to 1.3 Billion by 2050. Therefore, the appropriate and timely stroke intervention is required to save healthcare costs and reduce the burden of the disease. Studies have reported the effectiveness of VR intervention not only in cognitive abilities but it has found to be simultaneously effective in improving other domains as attention and coordination with motor retraining. VR combined with a newly developed concept of motor priming has shown encouraging results in improving motor control and task execution in stroke patients. Further studies are needed to analyze the impact of motor priming with VR in stroke patients on varied neurological domains; hence the present study aims to investigate the impact of VR based motor priming on sensorimotor, functional and cognitive outcomes among sub-acute stroke patients rehabilitation.
Detailed Description
A total 62 patients will be recruited in the study. After voluntary consent, all the patients will be randomly divided into Group-A and B through the envelope method of simple random sampling. Patients in Group-A will be receiving VR based motor priming intervention while Group-B patients will be receiving Motor-Relearning Program as conventional therapy. Whereas, both the groups will be given 16 sessions of their respective protocol, comprising of 45 minutes, 4 times/week for the duration of 4 weeks. Pre and post assessment will be performed for each patient on all three quantitative outcome measures i.e. FMA-UE, CAHAI-13, and MoCA. A trial will be terminated, if the patient reported fatigue of \>8 out of 10 on the Visual Analogue Scale, unable to execute movements, reports pain, eye strain, or signs of volitional fatigue in hemiplegic or non-hemiplegic extremities.
Investigators
Jaza Rizvi
Principal Invesitgator
Ziauddin University
Eligibility Criteria
Inclusion Criteria
- •Male and female stroke patients aged 25-65 years
- •Patients who had an ischemic or hemorrhagic stroke in sub-acute phase of \< 3 months
- •Mild cognitive impairment i.e. \< 26 (19.0-25.2) on MoCA
- •Minimum Scoring of 28 in the Motricity Index
Exclusion Criteria
- •Diagnosed visual-perceptual ailments which may restrict task execution
- •Communication disorders such as aphasia or dysarthria which may impede cognitive assessment
- •Comorbidities such as elevated blood pressure (\>160mmhg/105 mmHg), heart diseases or chronic medical conditions
- •Major or active psychological illness and pre-existing dementia
Outcomes
Primary Outcomes
Sensorimotor function of hemiplegic upper extremity (Pre-Treatment)
Time Frame: Baseline
Sensorimotor function will be assessed through Fugl-Meyer Assessment Test where high values indicates increase in sensoimotor function
Sensorimotor function of hemiplegic upper extremity (Post-Treatment)
Time Frame: After 4 weeks
Sensorimotor function will be assessed through Fugl-Meyer Assessment Test where high values indicates increase in sensoimotor function
Functional ability of hemiplegic upper extremity (Pre-Treatment)
Time Frame: Baseline
Functional ability will be assessed through Chedoke Arm and Hand Activity Inventory-13 where high values indicates increase in Functional ability
Functional ability of hemiplegic upper extremity (Post-Treatment)
Time Frame: After 4 weeks
Functional ability will be assessed through Chedoke Arm and Hand Activity Inventory-13 where high values indicates increase in Functional ability
Cognitive Function (Pre-Treatment)
Time Frame: Baseline
Cognitive Function will be assessed using Montreal Cognitive Assessment where high values indicates increase in Cognitive Function
Cognitive Function (Post-Treatment)
Time Frame: After 4 weeks
Cognitive Function will be assessed using Montreal Cognitive Assessment where high values indicates increase in Cognitive Function